Short-Term Debt to Equity: coherus.com (CHRS)

Coherus Biosciences (CHRS) relies on contract manufacturing for its drugs, focusing instead on research and sales. The current development vector suggests a transition toward creating unique oncology treatments. The asset's market value dynamics on GURU.Markets stand at 0.04. High barriers to entry in the sector are driven by stringent FDA oversight and the complexity of protein synthesis, making the launch of new products extremely capital-intensive.

The investment attractiveness of Coherus Biosciences (CHRS) is based on the development of complex biosimilars with high technological barriers to entry. The ratio measures the share of short-term borrowings relative to equity, assessing liquidity risk during R&D financing. An analysis of the ratio between short-term liabilities and equity on GURU.Markets allows for the identification of hidden stagnation behind outward stability. A low level of this indicator confirms the fundamental resilience of Coherus Biosciences (CHRS) in the face of patent disputes.